期刊文献+

超高效液相色谱法测定艾塞那肽含量

Determination of exenatide in exenatide by ultra-performance liquid chromatography
下载PDF
导出
摘要 建立了艾塞那肽含量的UPLC测定方法。采用AcquityUPLCBEHC18柱(1.7μm,2.1mm×50mm),检测波长为214nm,梯度洗脱,流动相A:0.1mol/L的四乙基高氯酸铵溶液;流动相B:100%乙腈溶液;流速为O.2mL/min,进样量为1.4μL,柱温为50℃。结果表明,艾塞那肽质量浓度在0.04~0.4mg/mL内与峰面积呈良好的线性关系,平均回收率为100.1%;稳定性实验表明,室温下艾塞那肽溶液8h内能稳定存在。艾塞那肽质量分数平均在98%以上,满足纯度要求。该检测方法能够快速简便地测定艾塞那肽质量分数,且成本较低,精度较高,适用于艾塞那肽的质量控制。 A UPLC method is established for the determination of exenatide. The experiment is performed with an Acquity BEH C18 ( 1.7 μm, 2. 1 × 50 mm) column and the mobile phase consisting of aeetonitrile and 0. 1% tetraethylammonium perchlorate with gradient elution. The flow rate of 0. 2 mL/min and the injection volume of 1.4 μL as well as the column temperature of 40℃ are employed. The result shows that the calibration curve for exenatide is linear within the range of 0.0g -0.4 mg/mL. The average recovery is 100. 1%. Stability tests show that the exenatide is stable within 8 hours at room temperature. The average determination of exenatide is above 98%. The method is proved to be rapid and accurate and can be used for the quality control of exenatide.
出处 《现代化工》 CAS CSCD 北大核心 2015年第7期164-166,168,共4页 Modern Chemical Industry
关键词 艾塞那肽 超高效液相色谱法 含量测定 exenatide UPLC content determination
  • 相关文献

参考文献8

  • 1Renate E van Genugten, Daniel H van Raalte, et al. Dose glucagonlike peptide-I receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide [ J ]. Diabetes Research and Clinical Practice,2009,86:26 - 34.
  • 2宣吉明,高静,黄景彬,林亚玲,鲁莹,钟延强.艾塞那肽缓释微球的制备和体外释放的研究[J].第二军医大学学报,2011,32(7):772-775. 被引量:8
  • 3Liu Bin, Dong Qingguang, M Wang engshu, et al. Preparation, char- acterization, and pharmacodynamics of exenatide-loaded poly ( D, L- lactic-co-glycolic acid) mierospheres [ J ]. Ctem Pharm Bull, 2010, 58( 11 ) :1474 - 1479.
  • 4刘玉雪,付金香,赖伊丽,薛志婧,孔毅.RP-HPLC法测定醋酸艾塞那肽的含量[J].西北药学杂志,2010,25(2):90-91. 被引量:2
  • 5Xuan Jiming, Lin Yaling, Huang Jingbin, et al. Exenatide-loaded PL- GA microspheres with important glycemic control:In vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administra- tion to SD rats[ J]. Peptides ,2013,46 : 172 - 179.
  • 6石琳,董庆光,王春雨,刘斌,孔维,陈妍.HPLC法测定注射用艾塞那肽中主药的含量[J].中国当代医药,2009,16(8):122-123. 被引量:5
  • 7Li Kun, Yu Lin, Liu Xiaojun,et al. A long-acting formulation of poly- peptide drag exenatide in treatment of diabetes using an injectable block copolymer hydrogel [ J ]. Biomaterials ,2013,34:2834 - 2842.
  • 8Liang Rongcai, Zhang Renyu, X Liang,et al. Stability of exenatide in poly(D,L-lactide-co-glycalide) solutions:A simplified investigation on the peptide degradation by the polymer[ J]. European Journal of Pharmaceutical Sciences ,2013,50:502 - 510.

二级参考文献16

  • 1杨涛,杨永年.Exenatide和β细胞功能[J].国外医学(内分泌学分册),2005,25(1):18-22. 被引量:9
  • 2谭兴容,王毅,杨刚毅.Exendin-4与糖尿病治疗[J].重庆医学,2006,35(10):904-906. 被引量:8
  • 3Goke R, Linn T, Schmidt H, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-eells[J]. J Biol Chem, 1993,268 : 19650-19655.
  • 4Hiles R, Slone T, Serota D. Parotid gland basophilic loci in mice administered the peptide AC2993(synthetic exendin-4) by subcutaneous injection for periods of 13 to 26 weeks[J]. Toxicol Sci, 2003,72 : 384.
  • 5Christel C M,DeNardo D F. Release of exendin-4 is controlled by mechanical action in Gila Monsters, Heloderma suspectum [J]. Comparat Biochem Physiol Mol Integr Physiol, 2006,143 85-88.
  • 6Nielsen L L,Young A A,Parkes D G. Pharmacolog of exenatide (synthetic exendin-4):a porential therapeutic for improved control of type 2 diabetes[J]. Regulatory Peptides, 2004,117: 77-88.
  • 7Wu J H,Wu L,Xu X Q,Xu X Y,Yin X J,Chen Y J,et al. Microspheres made by W/O/O emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin[J]. J Pharm Sci, 2009,98 : 2051-2058.
  • 8Ciombor D M,Jaklenee A, Liu A Z, Thanos C, Rahman N, Weston P,et al. Encapsulation of BSA using a modified W/O/O emulsion solventremoval method [J]. J Microencapsul, 2006, 23 : 183-194.
  • 9Kwak H H ,Shim W S,Son M K. Pharmaeokinetics and efficacy of a biweekly dosage formulation of exenatide in zucker diabetic fatty (ZDF) Rats[J]. Pharm Res,2009,26:2504-2512.
  • 10Meinel L,llli O E,Zapf J ,Malfanti M,Peter Merkle H,Gander B. Stabilizing insulin-like growth factorI in poly(D, L-lactideeo-glycolide) microspheres[J]. J Contr Res,2001,70(1-2) :193-202.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部